Two Sigma Advisers
AIMT

Two Sigma Advisers’s Aimmune Therapeutics AIMT Stock Holding History

Two Sigma Advisers’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-251,800
Closed -$8.68M – 2695
2020
Q3 		$8.68M Buy
251,800
+176,700
+235% +$3.76M 0.02% 582
2020
Q2 		$1.25M Buy
75,100
+43,000
+134% +$730K ﹤0.01% 1464
2020
Q1 		$463K Buy
+32,100
New +$820K ﹤0.01% 1841
2019
Q1 		– Sell
-40,800
Closed -$976K – 2495
2018
Q4 		$976K Sell
40,800
-7,000
-15% -$181K ﹤0.01% 1494
2018
Q3 		$1.3M Sell
47,800
-100
-0.2% -$2.83K ﹤0.01% 1404
2018
Q2 		$1.29M Buy
47,900
+21,500
+81% +$658K ﹤0.01% 1500
2018
Q1 		$840K Buy
+26,400
New +$929K ﹤0.01% 1625

Two Sigma Advisers's AIMT Position: Q4 2020 in Review

Two Sigma Advisers sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 251,800 shares — an estimated $8.68M sold.

Two Sigma Advisers first reported a position in AIMT in Q1 2018 and held it in 7 quarters. The position peaked at $8.68M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Two Sigma Advisers reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Two Sigma Advisers sold 251,800 Aimmune Therapeutics shares in Q4 2020, an estimated $8.68M.
  • Two Sigma Advisers first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 7 quarters.
  • Two Sigma Advisers's Aimmune Therapeutics position peaked at $8.68M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Two Sigma Advisers's 13F filing for Q4 2020, filed 16 Feb 2021.